Oral Factor XIa Inhibitor Milvexian After a Recent Acute Coronary Syndrome: Rationale and Design of the Phase 3 (Librexia ACS)
作者：C. Michael Gibson [1];M. Cecilia Bahit [2];Roxana Mehran [3];Shamir R. Mehta [4];Rasha Al Lamee [5];Shinya Goto [6];Jeffrey I. Weitz [7];Jay Horrow [8];Elliot S. Barnathan [9];Robert A. Harrington [10];Kenneth W. Mahaffey [11];Carolyn S.P. Lam [12];Karen S. Pieper [13];S. Claiborne Johnston [14];Graeme J. Hankey [15];Alexei N. Plotnikov [16];Danshi Li [17];Hsiaowei Deng [18];Philippe Gabriel Steg [19];
DOI：10.1016/j.ahj.2025.02.011